Sermorelin vs MK-677 (Ibutamoren): Switching Between Them

How Each Agent Raises Growth Hormone

Sermorelin and MK-677 both increase circulating growth hormone, but they do so through entirely separate receptor pathways. That distinction shapes everything from dosing timing to side-effect profiles.

Sermorelin (sermorelin acetate) is a 29-amino-acid peptide identical to the first 29 residues of endogenous GHRH. It binds the GHRH receptor on anterior pituitary somatotrophs and triggers GH release in a pulsatile fashion that mirrors the body's own secretory rhythm. Walker et al. demonstrated in a controlled pediatric trial (N=20) that sermorelin injections increased growth velocity from 3.8 cm/year to 6.1 cm/year over 12 months 1. The GH pulses sermorelin produces tend to peak 15 to 30 minutes post-injection and return to baseline within roughly 90 minutes, preserving the natural feedback loop between GH and somatostatin.

MK-677 works through an entirely different door. It is a non-peptide ghrelin mimetic that activates the growth hormone secretagogue receptor (GHS-R1a). Rather than mimicking GHRH, it replicates the signal ghrelin sends from the gut. Murphy et al. showed in a randomized, double-blind, placebo-controlled trial that oral MK-677 at 25 mg daily sustained elevated GH and IGF-1 concentrations across a full 24-hour sampling period in healthy older adults 2. IGF-1 levels rose by roughly 40% and remained elevated at the 12-month mark without evidence of tachyphylaxis.

The pulsatile-versus-sustained distinction matters clinically. Pulsatile GH secretion preserves receptor sensitivity. Sustained elevation may carry different metabolic consequences, particularly regarding glucose handling.

Efficacy Comparison: What the Evidence Actually Shows

No randomized controlled trial has placed sermorelin and MK-677 in the same study. Any comparison relies on cross-trial inference, which carries real limitations.

Sermorelin's evidence base leans heavily on pediatric GH deficiency. The Walker et al. trial confirmed its biological activity through growth velocity and GH stimulation testing 1. Adult data are more limited. A study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that sermorelin given nightly to adults over age 60 increased 24-hour integrated GH concentrations and improved body composition markers over 14 weeks.

MK-677 has a broader adult dataset. Beyond the Murphy et al. trial 2, Nass et al. published a two-year randomized trial (N=65) in healthy older adults showing that ibutamoren 25 mg/day increased GH and IGF-1 to levels seen in younger adults, with gains in fat-free mass of approximately 1.1 kg by month 12 3. That same trial, however, documented an increase in fasting glucose and a trend toward insulin resistance that demands monitoring.

A practical observation: sermorelin tends to produce more modest IGF-1 elevations (typically 15 to 25% above baseline in adult users) compared with MK-677's more consistent 35 to 50% increases. Whether higher IGF-1 translates to better clinical outcomes or simply greater metabolic risk remains an open question. The Endocrine Society's 2011 clinical practice guideline on GH use in adults emphasizes that IGF-1 should be kept within the age-adjusted normal range regardless of the agent used 4.

Side Effects: Different Mechanisms, Different Risks

The safety profiles of these two compounds reflect their distinct receptor targets. Understanding these differences is essential before considering a switch.

Sermorelin's side effects are generally mild and injection-site related. Facial flushing, headache, and local redness or swelling at the injection site are the most frequently reported reactions. Because sermorelin depends on an intact pituitary to work, it has a built-in ceiling: if the pituitary is already producing maximal GH output, sermorelin cannot push it further. That ceiling acts as a partial safety brake against GH excess.

MK-677's side-effect profile reflects ghrelin-pathway activation. The most clinically significant concern is its effect on glucose metabolism. In the Nass et al. two-year trial, fasting blood glucose increased by an average of 0.3 mmol/L, and several subjects developed impaired fasting glucose 3. MK-677 also reliably increases appetite (ghrelin's primary physiological role involves hunger signaling), which can be a benefit for sarcopenic patients or a problem for those managing body composition. Research published in Obesity Research documented weight gain driven partly by increased caloric intake in subjects taking MK-677.

Water retention and mild edema occur with both agents but are more pronounced with MK-677 due to sustained GH and IGF-1 elevation. Joint stiffness and carpal-tunnel-like symptoms occasionally surface during the first weeks of MK-677 use and typically resolve with dose reduction.

A comparison framework for clinical decision-making:

| Factor | Sermorelin | MK-677 | |---|---|---| | Route | Subcutaneous injection | Oral (capsule) | | GH pattern | Pulsatile | Sustained 24-hour | | IGF-1 rise | 15-25% typical | 35-50% typical | | Glucose impact | Minimal | Clinically relevant | | Appetite effect | Negligible | Significant increase | | Tachyphylaxis risk | Possible after months | Not observed at 2 years | | Requires intact pituitary | Yes | Yes | | FDA approval status | Previously approved (discontinued) | Investigational |

Is Sermorelin Better Than MK-677?

"Better" depends entirely on the clinical goal, the patient's metabolic profile, and their tolerance for injections versus glucose-related risks.

Sermorelin may be the preferred choice for patients who want physiologic GH pulsatility, have pre-diabetes or insulin resistance concerns, or prefer a compound with a former FDA-approval track record. Its lower IGF-1 ceiling also suits patients whose goal is anti-aging optimization rather than aggressive recomposition.

MK-677 may be preferred when injection adherence is a barrier (it is taken orally once daily), when the goal includes appetite stimulation in cachectic or sarcopenic patients, or when a more sustained IGF-1 elevation is therapeutically desired. A study in the American Journal of Clinical Nutrition confirmed that MK-677 reversed diet-induced nitrogen wasting, suggesting utility in catabolic states.

Neither agent is categorically superior. The choice depends on the specific clinical scenario. For a 55-year-old male with borderline HbA1c of 5.8% seeking GH optimization, sermorelin's minimal glucose impact gives it an edge. For a 68-year-old female with poor appetite and sarcopenia who cannot tolerate injections, MK-677's oral dosing and appetite-stimulating properties may be more appropriate.

How to Switch from Sermorelin to MK-677

Switching between these agents is not a simple swap. The different receptor pathways, half-lives, and metabolic effects require a structured transition.

Most clinicians experienced with peptide therapy recommend a short washout period of 5 to 7 days after discontinuing sermorelin before starting MK-677. This is not because of a dangerous interaction (the two act on different receptors) but because overlapping GH stimulation from residual sermorelin activity and newly initiated MK-677 could produce supraphysiologic IGF-1 levels that are difficult to interpret on labs drawn during the overlap window.

Before switching, baseline labs should include IGF-1, fasting glucose, fasting insulin, and HbA1c. After initiating MK-677 (typically at 12.5 mg daily for the first two weeks, then titrating to 25 mg), repeat IGF-1 and fasting glucose at the four-week mark. The Endocrine Society recommends maintaining IGF-1 within the upper half of the age-adjusted reference range during any form of GH-axis therapy 4.

The transition protocol in brief:

1. Obtain pre-switch labs (IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel).
2. Discontinue sermorelin. Allow 5 to 7 days of washout.
3. Begin MK-677 at 12.5 mg orally each evening (bedtime dosing reduces daytime hunger and takes advantage of GH's natural nocturnal peak).
4. After two weeks without adverse effects, titrate to 25 mg nightly if IGF-1 target has not been reached.
5. Recheck IGF-1 and fasting glucose at 4 weeks post-initiation, then every 3 months thereafter.

How to Switch from MK-677 to Sermorelin

Switching in the opposite direction, from MK-677 to sermorelin, carries a different set of considerations. The primary concern is that MK-677's sustained GH/IGF-1 elevation over the preceding weeks or months may have partially downregulated somatostatin tone.

A washout of 7 to 14 days is reasonable when transitioning off MK-677. The compound's elimination half-life is approximately 5 hours, but its pharmacodynamic effects on IGF-1 persist well beyond drug clearance because IGF-1 has its own half-life of roughly 12 to 16 hours and is buffered by binding proteins. Research on IGF-1 kinetics shows that IGF-1 levels may take 1 to 2 weeks to return to a new steady state after a GH-axis intervention changes.

After the washout, sermorelin is typically initiated at 200 to 300 mcg subcutaneously each evening. Response assessment via IGF-1 should occur at 4 to 6 weeks. Because sermorelin produces more modest IGF-1 changes, patients switching from MK-677 may initially perceive a reduction in subjective effects (less water retention, decreased appetite, possibly less perceived "fullness" of muscle). This is expected and does not indicate treatment failure.

Patients with MK-677-associated glucose elevations often see fasting glucose normalize within 2 to 4 weeks of discontinuation. Monitoring glucose during the transition helps confirm metabolic recovery.

Combining Both Agents: Why Most Clinicians Advise Against It

Some patients ask about using sermorelin and MK-677 simultaneously. While no published data directly evaluate the combination, most peptide-therapy clinicians discourage concurrent use for practical and safety reasons.

Both agents stimulate GH release through different pathways, and the additive effect on IGF-1 could push levels well above the age-adjusted normal range. Sustained supraphysiologic IGF-1 has been associated with increased risk of certain malignancies in epidemiologic data. A large prospective analysis published in The Lancet found that IGF-1 concentrations in the top quintile were associated with increased colorectal cancer risk (OR 1.49 to 95% CI 1.14 to 1.94). While this does not prove causation, it underscores why the Endocrine Society advises keeping IGF-1 within normal limits.

The glucose-related risks of MK-677 would also compound with any glucose effects from elevated GH. Stacking two GH secretagogues without published safety data to guide dosing creates unpredictable risk.

If the clinical rationale for combining agents is inadequate response to monotherapy, the appropriate next step is not dual secretagogue therapy but rather evaluation for true GH deficiency via provocative testing and consideration of recombinant GH (somatropin) under endocrinology guidance, as outlined in the Endocrine Society clinical practice guideline [4].

Regulatory and Access Considerations

Sermorelin's regulatory history is unusual. It received FDA approval in 1997 as Geref Diagnostic for evaluating pituitary GH-secretory capacity. The therapeutic version (Geref) was also approved but was voluntarily withdrawn from the US market for commercial (not safety) reasons. It remains available through compounding pharmacies under a physician's prescription, regulated under the FDA's pharmacy compounding framework.

MK-677 has never received FDA approval for any indication. It is classified as an investigational compound. Access in clinical practice occurs through research protocols or, more commonly, through wellness and anti-aging clinics operating under the practice of medicine. Patients should be informed of its investigational status.

This regulatory asymmetry can influence the decision to switch. Some patients transition from MK-677 to sermorelin specifically because they prefer a compound with a historical approval pathway and a more established compounding infrastructure.

Monitoring Schedule for Either Agent

Regardless of which agent a patient uses, ongoing monitoring prevents complications and confirms therapeutic benefit.

The Endocrine Society's 2011 guideline on adult GH replacement provides the closest applicable monitoring framework [4]. While written for recombinant GH, its principles apply to any intervention modulating the GH-IGF-1 axis:

• IGF-1: Measure at baseline, 4 weeks after starting or switching, then every 3 to 6 months. Target: upper half of age-adjusted normal range.
• Fasting glucose and HbA1c: Baseline and every 3 months for the first year, especially with MK-677. Annual thereafter if stable.
• Lipid panel: Baseline and every 6 months. GH-axis therapy can alter lipoprotein metabolism.
• Body composition: DXA or bioimpedance at baseline and 6 to 12 months to document objective changes in lean mass and fat mass.
• Symptom assessment: Sleep quality, energy, recovery from exercise, and subjective well-being. Validated tools like the QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) can track changes systematically.

Dose adjustments should be lab-driven. If IGF-1 exceeds the age-adjusted reference range on either agent, reduce the dose before the next lab check.